Trial: Checkmate-816

Surgical outcomes from the Phase III CheckMate 816 trial

CheckMate-816: what does the data tell us?

Event-free survival results from CheckMate 816

Dr. Patrick Forde Discusses 3-Year CheckMate 816 NSCLC Results at ASCO 2023

Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022

GRACE - Global Resource for Advancing Cancer Education

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IO

The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies - Lung Cancer OncTalk 2022

GRACE - Global Resource for Advancing Cancer Education

Dr KRIPA BAJAJ | SURGICAL OUTCOMES FROM THE PHASE 3 CHECKMATE 816 TRIAL Update 19 February 2022

CRSF - Cancer Research and Statistic Foundation

Cancer trials - IMPOWER010; CheckMate 816; Drug Dosing; Swiss Edition w/ Timothee Olivier

Vinay Prasad MD MPH

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023

GRACE - Global Resource for Advancing Cancer Education

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC

European Society for Medical Oncology (ESMO)

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLC

GRACE - Global Resource for Advancing Cancer Education

Neoadjuvant Nivolumab in Resectable Lung Cancer | NEJM

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

Perioperative therapies in NSCLC

Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022

European Society for Medical Oncology (ESMO)

The rationale and trial design of the NADIM II trial